CFCharles S. Fuchs

Charles S. Fuchs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles S. Fuchs has a total of 394 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

    by Fang-Shu Ou, Daniel H. Ahn, Jesse G. Dixon, Axel Grothey, Yiyue Lou, Pashtoon M. Kasi, Joleen M. Hubbard, Eric Van Cutsem, Leonard B. Saltz, Hans-Joachim Schmoll, et al.

    Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS). Patients and Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the 12-week scan. Lesion-based response criteria were defined for each patient as follows: PL only, SL only, RL only, and varied responses (mixture of RL, SL, and PL). Lesion-based response criteria and OS were correlated using stratified multivariable Cox models. The concordance between OS and classifications was measured using the C statistic. Results: Among 10,551 patients with mCRC from 17 first-line studies, varied responses were noted in 51.6% of patients, among whom, 3.3% had RL/PL at 12 weeks. Among patients with RL/SL, 52% had stable disease (SD) by RECIST 1.1, and they had a longer OS (median OS (mOS) = 19.9 months) than those with SL only (mOS = 16.8 months, HR (95% CI) = 0.81 (0.76, 0.85), p < 0.001), although a shorter OS than those with RL only (mOS = 25.8 months, HR (95% CI) = 1.42 (1.32, 1.53), p < 0.001). Among patients with SL/PL, 74% had SD by RECIST 1.1, and they had a longer OS (mOS = 9.0 months) than those with PL only (mOS = 8.0 months, HR (95% CI) = 0.75 (0.57, 0.98), p = 0.040), yet a shorter OS than those with SL only (mOS = 16.8 months, HR (95% CI) = 1.98 (1.80, 2.18), p < 0.001). These associations were consistent across treatment regimen subgroups. The lesion-based response criteria showed slightly higher concordance than RECIST 1.1, although it was not statistically significant. Conclusion: Varied responses at first restaging are common among patients receiving first-line therapy for mCRC. Our lesion-based measurement criteria allowed for better mortality discrimination, which could potentially be informative for treatment decision-making and influence patient outcomes.


  • Open Access

    Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database

    by En Cheng, Holly N. Blackburn, Kimmie Ng, Donna Spiegelman, Melinda L. Irwin, Xiaomei Ma, Cary P. Gross, Fred K. Tabung, Edward L. Giovannucci, Pamela L. Kunz, et al.

    Among adults aged younger than 50 years in the US, colorectal cancer (CRC) represents the second most common cancer diagnosis and the third leading cause of cancer death.1 Although there is no unequivocal definition of early-onset CRC, age younger than 50 years appears to be a common criterion in the published literature.2,3 The use of this criterion is driven, in part, by the recommendations across US independent expert panels published in the past 2 decades for CRC screening at age 50 years for individuals with the mean risk level.4-11


  • Open Access

    Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

    by Justin C. Brown, Michael H. Rosenthal, Chao Ma, Sui Zhang, Halla S. Nimeiri, Nadine J. McCleary, Thomas A. Abrams, Matthew B. Yurgelun, James M. Cleary, Douglas A. Rubinson, et al.

    Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D3 (4000 IU) or standard-dose (400 IU) vitamin D3. Body composition was measured with abdominal computed tomography at enrollment (baseline) and after cycle 8 of chemotherapy (16 weeks). As compared with standard-dose vitamin D3, high-dose vitamin D3 did not significantly change body weight [−0.7 kg; (95% CI: −3.5, 2.0)], body mass index [−0.2 kg/m2; (95% CI: −1.2, 0.7)], muscle area [−1.7 cm2; (95% CI: −9.6, 6.3)], muscle attenuation [−0.4 HU; (95% CI: −4.2, 3.2)], visceral adipose tissue area [−7.5 cm2; (95% CI: −24.5, 9.6)], or subcutaneous adipose tissue area [−8.3 cm2; (95% CI: −35.5, 18.9)] over the first 8 cycles of chemotherapy. Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D3, vs standard-dose vitamin D3, to standard chemotherapy did not result in any changes in body composition.


  • Open Access

    Sugar-sweetened beverage and sugar intake during adolescence and risk of colorectal cancer precursors: a large prospective U.S. cohort study

    by Hee-Kyung Joh, Dong Hoon Lee, Jinhee Hur, Katharina Nimptsch, Yoosoo Chang, Hyojee Joung, Xuehong Zhang, Leandro F. M. Rezende, Jung Eun Lee, Kimmie Ng, et al.

    OBJECTIVE: To examine the associations of adolescent sugar-sweetened beverage (SSB) and sugar intake with risk of colorectal cancer (CRC) precursors. DESIGN: Prospective cohort study. SETTING: Nurses’ Health Study II (1998-2015), United States. PARTICIPANTS: 33106 women who completed a validated high school food frequency questionnaire about adolescent diet in 1998 and underwent lower gastrointestinal endoscopy between 1999 and 2015. MAIN OUTCOME MEASURES: Incident CRC precursors confirmed by medical record review. RESULTS: During follow-up, 2909 conventional adenoma, 1082 high-risk adenoma (≥1 cm in size, villous, high-grade dysplasia, or number ≥2), and 2355 serrated lesions were identified. Independent of adult intake, adolescent SSB and sugar intake was positively associated with risk of total and high-risk adenoma. Comparing ≥2 servings/day v v <1 serving/week) and 1.51 (1.26 to 1.82) for the highest quintile of total fructose (P≤0.024 for interaction). Neither SSB nor sugar intake during adolescence was associated with risk of serrated lesions. CONCLUSIONS: Independent of adult intake, adolescent SSB and sugar intake was positively associated with colorectal adenoma, especially high-risk rectal adenoma. Our findings suggest that adolescence may be a critical developmental period of enhanced susceptibility to high sugar intake, possibly promoting precancerous lesions of CRC arising through the adenoma-carcinoma sequence. What is already known on this topic: - Relatively few studies have examined the association between sugar intake and colorectal neoplasia, and most prospective studies have reported null associations. - Considering the long process of colorectal carcinogenesis and recent upward trends in early-onset colorectal cancer, early-life diet may be etiologically relevant. - However, data on the relationship between high sugar intake during early-life and risk of colorectal neoplasia are lacking. What this study adds: - Higher intake of sugar-sweetened beverages (SSBs) and sugars during adolescence was significantly associated with increased risk of total and high-risk adenoma, especially high-risk rectal adenoma, but not serrated lesions. - Positive associations were stronger among women with low fruit, vegetable, or fiber intake during adolescence. - Our results suggest that limiting sugar intake and replacing SSBs with healthy alternatives during early-life may help to reduce risk of colorectal cancer precursors.

  • Open Access

    Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

    by Ian Chau, Nicolas Penel, Andres O. Soriano, Hendrik-Tobias Arkenau, Jennifer Cultrera, Rafael Santana-Davila, Emiliano Calvo, Christophe Le Tourneau, Lars Zender, Johanna C. Bendell, et al.

    Ramucirumab (anti-VEGFR2) plus pembrolizumab (anti-PD1) demonstrated promising antitumor activity and tolerability among patients with previously treated advanced cancers, supporting growing evidence that combination therapies modulating the tumor microenvironment may expand the spectrum of patients who respond to checkpoint inhibitors. Here we present the results of this combination in first-line patients with metastatic G/GEJ cancer. Twenty-eight patients (≥18 years) with no prior systemic chemotherapy in the advanced/metastatic setting received ramucirumab (8 mg/kg days 1 and 8) plus pembrolizumab (200 mg day 1) every 3 weeks as part of JVDF phase 1a/b study. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Tumors were PD-L1-positive (combined positive score ≥ 1) in 19 and -negative in 6 patients. Eighteen patients experienced grade 3 treatment-related adverse events, most commonly hypertension (14%) and elevated alanine/aspartate aminotransferase (11% each), with no grade 4 or 5 reported. The ORR was 25% (PD-L1-positive, 32%; PD-L1-negative, 17%) with duration of response not reached. PFS was 5.6 months (PD-L1-positive, 8.6 months; PD-L1-negative, 4.3 months), and OS 14.6 months (PD-L1-positive, 17.3 months; PD-L1-negative, 11.3 months). Acknowledging study design limitations, ramucirumab plus pembrolizumab had encouraging durable clinical activity with no unexpected toxicities in treatment-naïve biomarker-unselected metastatic G/GEJ cancer, and improved outcomes in patients with PD-L1-positive tumors.


  • Open Access

    The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)

    by En Cheng, Sui Zhang, Fang-Shu Ou, Brian Mullen, Kimmie Ng, Leonard B. Saltz, Donna Niedzwiecki, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, et al.

    Background: Hyperinsulinemia is considered to be important in the development of colon cancer, but few studies have investigated the associations of hyperinsulinemia with colon cancer survival via dietary scores. Methods: Empirical dietary index for hyperinsulinemia (EDIH) was derived to assess the insulinemic potential of daily diets reflecting the long-term insulin exposure, with higher (more positive) scores indicating higher insulinemic diets. We prospectively estimated the HRs and 95% confidence intervals (CI) to investigate the association of EDIH with disease-free, recurrence-free, and overall survival among patients with stage III colon cancer (1999–2009) enrolled in a randomized adjuvant chemotherapy trial (CALGB 89803). Results: Of 1,024 patients (median follow-up: 7.3 years), 311 died, 350 had recurrences, and 394 had events for disease-free survival. Compared with patients in the lowest quintile of EDIH, the corresponding HRs of patients in the highest quintile for disease-free survival events, cancer recurrence, and overall mortality were 0.80 (95% CI, 0.56–1.15), 0.76 (95% CI, 0.51–1.11), and 0.77 (95% CI, 0.52–1.14). Conclusions: Higher EDIH was not associated with the risk of colon cancer recurrence or mortality in this population of patients with stage III colon cancer. Impact: EDIH, as a measure of dietary insulinemic potential, may be associated with colon cancer risk but not survival in patients with late-stage colon cancer.


  • Open Access

    Tumor-Immune Partitioning and Clustering (TIPC) algorithm reveals distinct signatures of tumor-immune cell interactions within the tumor microenvironment

    by Mai Chan Lau, Jennifer Borowsky, Juha P. Väyrynen, Koichiro Haruki, Melissa Zhao, Andressa Dias Costa, Simeng Gu, Annacarolina da Silva, Kota Arima, Joe Yeong, et al.

    Growing evidence supports the importance of understanding tumor-immune spatial relationship in the tumor microenvironment in order to achieve precision cancer therapy. However, existing methods, based on oversimplistic cell-to-cell proximity, are largely confounded by immune cell density and are ineffective in capturing tumor-immune spatial patterns. Here we developed a novel computational algorithm, termed Tumor-Immune Partitioning and Clustering (TIPC), to offer an effective solution for spatially informed tumor subtyping. Our method could measure the extent of immune cell partitioning between tumor epithelial and stromal areas as well as the degree of immune cell clustering. Using a U.S. nation-wide colorectal cancer database, we showed that TIPC could determine tumor subtypes with unique tumor-immune spatial patterns that were significantly associated with patient survival and key tumor molecular features. We also demonstrated that TIPC was robust to parameter settings and readily applicable to different immune cell types. The capability of TIPC in delineating clinically relevant patient subtypes that encapsulate tumor-immune spatial relationship, immune density, and tumor morphology is expected to shed light on underlying immune mechanisms. Hence, TIPC can be a useful bioinformatics tool for effective characterization of the spatial composition of the tumor-immune microenvironment to inform precision immunotherapy.

  • Open Access

    Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma

    by Katherine Minjee Chung, Jaffarguriqbal Singh, Lauren Lawres, Kimberly Judith Dorans, Cathy Garcia, Daniel B. Burkhardt, Rebecca Robbins, Arjun Bhutkar, Rebecca Cardone, Xiaojian Zhao, et al.

    SUMMARY: Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well understood. Leveraging an autochthonous mouse model, we demonstrate a causal and reversible role for obesity in early PDAC progression, showing that obesity markedly enhances tumorigenesis, while genetic or dietary induction of weight loss intercepts cancer development. Bulk and single cell molecular analyses of human and murine samples define microenvironmental consequences of obesity that promote tumor development rather than new driver gene mutations. We observe increased inflammation and fibrosis and also provide evidence for significant pancreatic islet cell adaptation in obesity-associated tumors. Specifically, we identify aberrant islet beta cell expression of the peptide hormone cholecystokinin (CCK) in tumors as an adaptive response to obesity. Furthermore, beta cell CCK expression promotes oncogenic Kras -driven pancreatic ductal tumorigenesis. Our studies argue that PDAC progression is driven by local obesity-associated changes in the tumor microenvironment – rather than systemic effects – and implicate endocrine-exocrine signaling beyond insulin in PDAC development. Furthermore, our demonstration that these obesity-associated adaptations are reversible supports the use of anti-obesity strategies to intercept PDAC early during progression.


  • Omitted Disclosures of Potential Conflicts of Interest in Articles Published in JAMA Oncology

    by Charles S. Fuchs

    To the Editor I write to amend my disclosures of potential conflicts of interest in articles1-11 published in JAMA Oncology in 2016 through 2018. In 1 of these articles, “Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial,”8 which represented a clinical trial of a novel therapeutic in patients with gastric cancer, I reported relevant disclosures related to consulting work with the biotechnology and pharmaceutical industry focused on cancer drug development as follows: “Dr Fuchs has been a consultant for Eli Lilly, Entrinsic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Dicerna, Bayer, Agios, Gilead Sciences, Five Prime Therapeutics, and Taiho.” However, that disclosure did not include my relationships at the time with Celgene and KEW. The other studies assessed the role of obesity, diet, lifestyle habits, and genetic mutations in cancer risk and outcome,1-7,9-11 and for those articles I reported that I had no potential conflicts of interest to disclosure. With respect to these analyses of obesity, diet, lifestyle habits, and genetic mutations and cancer, I did not consider that my consulting work in drug development represented a potential conflict of interest or a relevant financial activity to the submitted works. Additionally, I did not believe that my consulting work would be perceived by readers to have influenced or give the appearance of potentially influencing analyses of obesity, diet, lifestyle habits, and genetic mutations in cancer risk and outcome.


  • Top Cited Papers

    Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    by Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah-Eddin Al-Batran, Eric Van Cutsem, David H Ilson, Maria Alsina, Ian Chau, Jill Lacy, et al.